A new multi-institution study spearheaded by researchers at Florida State University and the University of California, Los Angeles suggests a tiny protein could play a major role in combating heart failure related to Duchenne muscular dystrophy (DMD), the most common lethal genetic disorder among children.
In collaboration with scientists from across the nation, FSU researchers found that increased levels of the protein sarcospan improve cardiac function by reinforcing cardiac cell membranes, which become feeble in patients with DMD.
Their findings were published in the journal JCI Insight.
The condition, which typically afflicts young boys, is caused by a mutation that prevents the body from producing dystrophin, a protein crucial to the health of skeletal, respiratory and cardiac muscles. Advances in treatment for certain types of DMD-related muscle degradation have helped to prolong patients’ lifespans. However, as DMD patients age, their heart function declines dramatically.
“Patients typically live to 20 or 30 years of age,” said lead author Michelle Parvatiyar, an assistant professor in the Department of Nutrition, Food and Exercise Sciences in FSU’s College of Human Sciences. “There have been important improvements in respiratory care, which used to be what a majority of patients would succumb to. Now, in their 20s and 30s, they’re often succumbing to cardiomyopathy. The heart is functioning with a major component of the cell membrane missing. Over time, it wears out.”
The study was part of continued efforts by UCLA biologist Rachelle H. Crosbie, the study’s corresponding author, who previously identified sarcospan as a protein that could improve mechanical support in skeletal cell membranes lacking dystrophin. Her finding buoyed DMD researchers and affirmed sarcospan’s potential as an effective tool in the fight against the condition.
“But nobody had really looked at how increasing the levels of this protein might affect the heart,” Parvatiyar said.
Using a unique mouse model with a dearth of dystrophin, Parvatiyar and her collaborators did just that.
In their study, the team found that while it’s is not a like-for-like replacement for dystrophin, an overexpression of sarcospan in cardiac cells seems to do the job of stabilizing cell membranes. Even under stress, researchers found, sarcospan overexpression was able to improve the membrane defect in dystrophin-deficient cells.
“Sarcospan doesn’t quite do the job of dystrophin, but it acts as a glue to stabilize the membrane and hold protein complexes together when dystrophin is lacking,” said Parvatiyar, explaining a concept developed by Crosbie.
Cardiac measurements confirmed that sarcospan does protect the cell membrane even when the heart is placed under stress. Study co-author and FSU College of Medicine Associate Professor Jose Pinto performed the measurements, along with FSU graduate student Karissa Dieseldorff Jones and University of Miami Miller School of Medicine research assistant Rosemeire Takeuchi Kanashiro.
In addition to serving as a kind of stabilizing glue, researchers said sarcospan could also act as a scaffold that supports other essential proteins at the cell membrane. That function could allow sarcospan to carry mini versions of dystrophin — which, in its normal state, has a long and unwieldy genetic code — to the edges of cardiac cells, where they could buttress the fragile membranes.
“The idea is that you could administer the sarcospan and the dystrophin at the same time, and the sarcospan could facilitate mini dystrophin localizing to the cell membrane and help hold those complexes in place,” Parvatiyar said.
Sarcospan’s two possible functions could augment existing DMD treatments, Parvatiyar said, or they could give rise to novel therapies that fortify weakened cardiac cell membranes and improve the quality of life for people with DMD.
In her previous position at UCLA, Parvatiyar had frequent interactions with DMD patients and their families. She said these interactions, and the unshakeable hope she’s witnessed in those suffering from DMD, continue to drive her and her colleagues in the search for new ways to combat this debilitating condition.
“Those were the first times in my life I’d ever had someone come up to me and thank me for my work,” she said. “Sometimes you can feel removed from it in the laboratory day after day. You see incremental progress. But to see people who are really yearning for help is motivating. Their positivity is incredibly inspiring.”
The Latest on: Duchenne muscular dystrophy
via Google News
The Latest on: Duchenne muscular dystrophy
- Parent Project Muscular Dystrophy's Duchenne Registry Participant Response Rate Increases Exponentially in 2020 Utilizing THREADon January 26, 2021 at 4:55 am
THREAD, an innovative technology and service provider that enables decentralized clinical research, and Parent Project Muscular ...
- Inspired by late son, Muhlenberg couple raise funds for muscular dystrophy researchon January 25, 2021 at 4:00 am
Anne L. and A. David Carroll Jr. of Muhlenberg Township helped raise more than $110,000 for muscular dystrophy research after the annual Black-N-Blue Ball, a major fundraiser for the cause ...
- 3) Edasalonexenton January 24, 2021 at 7:00 pm
There was more than one late-stage disappointment among companies developing drugs for the muscle-wasting disease Duchenne muscular dystrophy, but the demise of Catabasis’ edasalonexent was ...
- Avidity Biosciences Names Chief Technical Officeron January 22, 2021 at 6:52 am
La Jolla-based Avidity Biosciences, a biopharmaceuticals company which is developing oligonucleotide-based therapies, said this week that it as named W. Michael Flanagan, Ph.D., as its Chief Technical ...
- Will Sarepta's (SRPT) Overdependence on Exondys 51 Hurt?on January 21, 2021 at 7:35 am
Exondys 51 and Vyondys 53 — are indicated for the treatment of Duchenne muscular dystrophy (“DMD”). Sarepta’s stock has declined 18.3% in the past year against 13.9% increase of the industry. Sarepta ...
- Duchenne Muscular Dystrophy Market Analysis, Leading Companies, Emerging Drugs and Epidemiology Forecaston January 20, 2021 at 11:51 pm
DelveInsight's Duchenne Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast 2030 report delivers an in-depth understanding of the Duchenne Muscular Dystrophy, historical and ...
- Muscle metabolic remodelling patterns in Duchenne muscular dystrophy revealed by ultra-high-resolution mass spectrometry imagingon January 20, 2021 at 4:00 pm
Duchenne muscular dystrophy (DMD) is a common and severe X-linked myopathy, characterized by muscle degeneration due to altered or absent dystrophin. DMD has no effective cure, and the underlying ...
- Duchenne Muscular Dystrophy Treatment Market Outlook 2025, Size, Forecasts, Demand, Competitive Analysis, Growth Factors, Key Playerson January 19, 2021 at 11:18 pm
The propelling factors for the growth of the Duchenne muscular dystrophy (DMD) treatment market include the rising disease burden of Duchenne muscular dystrophy, increasing investments in ...
- Parent Project Muscular Dystrophy Invests $1 Million in Satellos Bioscience to Support New Regenerative Medicine Technologyon January 19, 2021 at 8:00 am
PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), ...
- You Searched For "duchenne muscular dystrophy"on January 17, 2021 at 6:03 am
Get Latest News, Breaking News about duchenne muscular dystrophy. Stay connected to all updated on duchenne muscular dystrophy ...
via Bing News